Although parathyroid hormone (PTH) replacement therapies are becoming available, their widespread use is limited by factors such as high cost, inability to accurately mimic physiological PTH levels, and potential risks like osteosarcoma [3,4]. This evidence concerns the gene PTH and osteosarcoma.